Death receptors as targets in cancer

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1723-1744

  Micheau, O ^a,b,c   Shirley, S ^a,b   Dufour, F ^a,b  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

apoptosis; Fas; resistance; therapy; TNF receptor superfamily; TRAIL; tumour targeting

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; APO 010; BEVACIZUMAB; BILIRUBIN; CARBOPLATIN; CETUXIMAB; CONATUMUMAB; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 4 ANTIBODY; DEATH RECEPTOR 5; DROZITUMAB; DULANERMIN; FAS LIGAND; FLUOROURACIL; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; MELPHALAN; MONOCLONAL ANTIBODY; PACLITAXEL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; THALIDOMIDE; TIGATUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANEMIA; APOPTOSIS; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHONDROSARCOMA; COLORECTAL CARCINOMA; CONSTIPATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; VOMITING;

APOPTOSIS; FAS; RESISTANCE; THERAPY; TNF-RECEPTOR SUPERFAMILY; TRAIL; TUMOUR TARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; HUMANS; NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84881338743     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12238     Document Type: Review

References (182)

1. Ashkenazi A, Dixit VM, (1998). Death receptors: signaling and modulation. Science 281: 1305-1308.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
3. Ashkenazi A, Holland P, Eckhardt SG, (2008). Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630.
4. Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, et al. (2009). c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr Relat Cancer 16: 443-453.
5. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B, (2007). Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 6: 1387-1399.
6. Baron AD, O'Bryant C, Choi Y, Royer-Joo S, Portera CC, (2011). Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 29 (15s): abstr 3581.
7. Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL, (2010). Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 28 (15s): abstr 8104.
8. Belch A, Sharma A, Spencer A, Tarantolo S, Bahlis N, Doval D, et al. (2010). Results of an international, randomized phase II clinical trial of bortezomib ± Mapatumumab (TRAIL-R1 agonist monoclonal antibody) for the treatment of relapsed/refractory multiple myeloma. Haematologica 96 (3s): abstr 1006.
9. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W, et al. (2007). Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 14: 2021-2034.
10. Blackhall FH, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, et al. (2010). A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small cell lung cancer (NSCLC). J Clin Oncol 28 (15s): abstr 7534.
11. Bodmer JL, Meier P, Tschopp J, Schneider P, (2000). Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 275: 20632-20637.
12. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A, (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 89: 206-214.
13. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. (2010). A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16: 1256-1263.
14. Chawla SP, Tabernero J, Kindler HL, Chiorean EG, LoRusso PM, Hsu M, et al. (2010). Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. J Clin Oncol 28 (15s): abstr 3102.
15. Chen W, Hou J, Zhao Y, Qiu L, Ke X, Wang Z, et al. (2012a). Circularly permuted TRAIL (CPT) combined with thalidomide for the treatment of relapsed or refractory multiple myeloma: an open-label, multicenter phase II clinical trial. 54th ASH annual meeting abstr 2958.
16. Chen W, Qiu L, Hou J, Zhang X, Ke X, Wang Z, et al. (2012b). Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients. 54th ASH annual meeting abstr 1857.
17. Chen W, Qiu L, Hou J, Zhao Y, Pan L, Yang S, et al. (2012c). Recombinant circularly permuted TRAIL (CPT) for the treatment of relapsed or refractory multiple myeloma: an open-label, multicenter phase II clinical trial. 54th ASH annual meeting abstr 78.
18. Chow LQ, Eckhardt G, Gustafson DL, O'Bryant C, Hariharan S, Diab S, et al. (2006). HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase 1 and PK study. J Clin Oncol 24 (18s): abstr 2515.
19. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al. (2001). Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166: 4891-4898.
20. Cohn AL, Tabernero J, Maurel J, Nowara E, Dubey S, Baker N, et al. (2012). Conatumumab (CON) plus FOLFIRI (F) or ganitumab (GAN) plus F for second-line treatment of mutant (MT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 30 (4s): abstr 534.
21. Cooper WA, Kohonen-Corish MR, Zhuang L, McCaughan B, Kennedy C, Screaton G, et al. (2008). Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 113: 135-142.
22. Costelli P, Aoki P, Zingaro B, Carbo N, Reffo P, Lopez-Soriano FJ, et al. (2003). Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ 10: 997-1004.
23. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S, (2001). Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390.
24. David E, Sinha R, Chen J, Sun SY, Kaufman JL, Lonial S, (2008). Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clin Cancer Res 14: 5090-5098.
25. Davidovich IA, Levenson AS, Levenson Chernokhvostov VV, (2004). Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance. Cancer Lett 211: 189-197.
26. Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, et al. (2012). First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 48: 547-563.
27. Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef C, (2012). Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol 105: 563-569.
28. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, et al. (2011). Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 29: 511-520.
29. Dobson CL, Main S, Newton P, Chodorge M, Cadwallader K, Humphreys R, et al. (2009). Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism. mAbs 1: 552-562.
30. Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, et al. (2011). Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 68: 733-741.
31. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, et al. (2005). Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 280: 22856-22867.
32. Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, et al. (2009). Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 28: 24.
33. Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, et al. (2010). The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 116: 549-555.
34. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, et al. (2011). APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-oncol 13: 155-164.
35. El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, Micheau O, et al. (2011). Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology 141: 663-673.
36. Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, et al. (2012). dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ 19: 1482-1494.
37. Etter AL, Bassi I, Germain S, Delaloye JF, Tschopp J, Sordat B, et al. (2007). The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. Gynecol Oncol 107: 14-21.
38. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, et al. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99: 491-504.
39. Fang F, Wang AP, Yang SF, (2005). Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin 26: 1373-1381.
40. Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, et al. (2005). DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 25: 2000-2013.
41. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ, (2008). Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 71: 507-516.
42. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, et al. (2010). Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25: 13-19.
43. Fridman JS, Lowe SW, (2003). Control of apoptosis by p53. Oncogene 22: 9030-9040.
44. Fulda S, Debatin KM, (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811.
45. Fulda S, Meyer E, Debatin KM, (2002). Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21: 2283-2294.
46. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG, (2005). Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4: 2026-2036.
47. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, et al. (2004). Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 (Suppl. 1): S86-S96.
48. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL, et al. (2006). Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12: 2640-2646.
49. Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U, et al. (2009). Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 87: 995-1007.
50. Garcia EJ, Lawson D, Cotsonis G, Cohen C, (2002). Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): prognostic significance. Appl Immunohistochem Mol Morphol 10: 210-217.
51. van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, et al. (2006). Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 24: 4998-5004.
52. Gliniak B, Le T, (1999). Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158.
53. Granci V, Bibeau F, Kramar A, Boissiere-Michot F, Thezenas S, Thirion A, et al. (2008). Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 44: 2312-2318.
54. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. (2008). Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90.
55. Greenblatt MS, Bennett WP, Hollstein M, Harris CC, (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
56. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E, et al. (2009). Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 36: 831-844.
57. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A, et al. (2004). Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 23: 8320-8332.
58. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer M, Lieberman G, et al. (2006). A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 24 (18S): abstr 3013.
59. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. (2010a). Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28: 2839-2846.
60. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. (2010b). A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16: 5883-5891.
61. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. (2003). Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23: 1428-1440.
62. Hori T, Kondo T, Kanamori M, Tabuchi Y, Ogawa R, Zhao QL, et al. (2010). Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett 287: 98-108.
63. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. (2008). A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 14: 3450-3455.
64. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, et al. (1999). Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4: 563-571.
65. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A, et al. (2000). A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39: 633-640.
66. Ivanov VN, Zhou H, Hei TK, (2007). Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res 67: 5397-5407.
67. Jacquemin G, Shirley S, Micheau O, (2010). Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells. Cell Mol Life Sci 67: 3115-3130.
68. Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morle A, Iessi E, et al. (2012). Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 97: 38-46.
69. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, et al. (2004). Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 64: 4900-4905.
70. Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, et al. (2008). Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 14: 7733-7740.
71. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, et al. (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564-567.
72. Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, et al. (2011). Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res 17: 3181-3192.
73. Karapetis CS, Clingan PR, Leighl NB, Durbin-Johnson B, O'Neill V, Spigel DR, (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC). J Clin Oncol 28 (15s): abstr 7535.
74. Kasubhai SM, Bendell JC, Kozloff M, Kapp AM, Ashkenazi A, Royer-Joo S, et al. (2012). Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 30 (15s): abstr 3543.
75. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S, (1999). Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741.
76. Kerr JF, Winterford CM, Harmon BV, (1994). Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-2026.
77. Kindler HL, Richards DA, Stephenson J, Garbo LE, Rocha Lima CS, Safran H, et al. (2010). A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 28 (15s): abstr 4035.
78. Kozloff M, Messersmith WA, Kapp AV, Ashkenazi A, Royer-Joo S, Portera CC, et al. (2012). Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 30 (15s): abstr 3552.
79. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, et al. (2010). Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 16: 5529-5538.
80. Kuijlen JM, Mooij JJ, Platteel I, Hoving EW, van der Graaf WT, Span MM, et al. (2006). TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 78: 161-171.
81. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J, (2005). Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 125: 1010-1019.
82. Kwon D, Choi K, Choi C, Benveniste EN, (2008). Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells. Biochem Biophys Res Commun 372: 870-874.
83. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, et al. (2003). Chemotherapy enhances TNF-related apoptosis-inducing Ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22: 1807-1816.
84. Lalaoui N, Morle A, Merino D, Jacquemin G, Iessi E, Morizot A, et al. (2011). TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS ONE 6: e19679.
85. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. (2001). Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385.
86. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. (2002). Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281.
87. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al. (2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149: 780-794.
88. Leithner K, Stacher E, Wurm R, Ploner F, Quehenberger F, Wohlkoenig C, et al. (2009). Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 65: 98-104.
89. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Roder C, et al. (2010). TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 88: 729-740.
90. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, et al. (2009). Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 27: 4413-4421.
91. Likui W, Qun L, Wanqing Z, Haifeng S, Fangqiu L, Xiaojun L, (2009). Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol 100: 396-400.
92. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, et al. (2006). Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clin Oncol 24 (18s): abstr 3047.
93. Liu X, Yue P, Khuri FR, Sun SY, (2004). p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64: 5078-5083.
94. Liu X, Yue P, Khuri FR, Sun SY, (2005). Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res 65: 9169-9175.
95. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. (2007). The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67: 4981-4988.
96. LoRusso PM, Hong DS, Heath E, Kurzrock R, Wang D, Hsu M, et al. (2007). First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 25 (18s): abstr 3534.
97. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM, (2005). Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11: 5188-5194.
98. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. (2005a). Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12: 773-782.
99. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM, (2005b). TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65: 11265-11270.
100. Macher-Goeppinger S, Aulmann S, Tagscherer KE, Wagener N, Haferkamp A, Penzel R, et al. (2009). Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin Cancer Res 15: 650-659.
101. McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, et al. (2013). Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol 160: 188-198.
102. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. (1997). A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7: 1003-1006.
103. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, de Witte T, et al. (1998). Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91: 2991-2997.
104. Meng RD, McDonald ER, 3rd, Sheikh MS, Fornace AJ, Jr, El-Deiry WS, (2000). The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 1: 130-144.
105. Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, et al. (2012). Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol 30: 4141-4147.
106. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O, (2006). Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26: 7046-7055.
107. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O, (2007). TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 11: 1299-1314.
108. Micheau O, Tschopp J, (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114: 181-190.
109. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J, (2001). NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 21: 5299-5305.
110. Min YJ, Lee JH, Choi SJ, Chi HS, Lee JS, Kim WK, et al. (2004). Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia. Leuk Res 28: 359-365.
111. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, et al. (2009). Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15: 5584-5590.
112. Morizot A, Merino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, et al. (2011). Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 18: 700-711.
113. Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y, (2010). Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro-oncol 12: 687-700.
114. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, et al. (2007). TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 139: 568-577.
115. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, Breard J, (2008). A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 27: 6012-6022.
116. Nesterov A, Nikrad M, Johnson T, Kraft AS, (2004). Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 64: 3922-3927.
117. Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM, et al. (2006). The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer J 12: 257-273.
118. Nieminen AI, Partanen JI, Hau A, Klefstrom J, (2007). c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J 26: 1055-1067.
119. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
120. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809.
121. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T, (2003). Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044.
122. Pan Y, Xu R, Peach M, Huang C, Branstetter D, Durbin B, et al. (2007). Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. J Clin Oncol 25 (18s): abstr 3535.
123. Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, et al. (2011). Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 105: 1830-1838.
124. Patnaik A, Wakelee HA, Mita M, Fitzgerald A, Hill M, Fox NL, et al. (2006). HGS-ETR2-a fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J Clin Oncol 24 (18s): abstr 3012.
125. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, et al. (2010). Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 70: 1101-1110.
126. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. (2008). Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112: 3807-3817.
127. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. (2007). Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13: 6187-6194.
128. Pordzik S, Petrovici K, Schmid C, Kroell T, Schweiger C, Kohne CH, et al. (2011). Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia. Hematology 16: 341-350.
129. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, et al. (2004). Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 64: 9105-9114.
130. Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, et al. (2009). Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 48: 2180-2191.
131. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D, et al. (2005). TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90: 612-624.
132. Roberts NJ, Zhou S, Diaz LA, Jr, Holdhoff M, (2011). Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2: 739-751.
133. Rocha Lima CM, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda JC, et al. (2012). Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Cancer Invest 30: 727-731.
134. Rocha Lima CS, Baranda JC, Wallmark J, Choi Y, Royer-Joo S, Portera CC, (2011). Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 29 (4S): abstr 546.
135. Rossi CR, Pasquali S, Mocellin S, Vecchiato A, Campana LG, Pilati P, et al. (2010). Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol 17: 3000-3007.
136. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ, (1998). Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414.
137. Ruiz de Almodovar C, Lopez-Rivas A, Redondo JM, Rodriguez A, (2002). Transcription initiation sites and promoter structure of the human TRAIL-R3 gene. FEBS Lett 531: 304-308.
138. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S, (2007). DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 14: 976-984.
139. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. (1998). Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205-1213.
140. Shankar S, Srivastava RK, (2004). Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156.
141. Shankar S, Chen X, Srivastava RK, (2005). Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62: 165-186.
142. Sharma S, de Vries E, Infante JR, Oldenhuis CN, Chiang L, Bilic S, et al. (2008). Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. J Clin Oncol 26 (20s): abstr 3538.
143. Shirley S, Morizot A, Micheau O, (2011). Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion. Recent Pat Anticancer Drug Discov 6: 311-323.
144. Sikic BI, Wakelee HA, von Mehren M, Lewis D, Calvert H, Plummer R, et al. (2007). A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 25 (18s): abstr 14006.
145. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK, (2003). Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400.
146. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. (2006). Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A 103: 8634-8639.
147. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, et al. (2007). Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 67: 8274-8284.
148. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. (2010). Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28: 1527-1533.
149. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, et al. (2011). Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29: 4442-4451.
150. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, et al. (2010). TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 16: 5734-5749.
151. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, et al. (2002). Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8: 3734-3740.
152. Sun W, Nelson D, Alberts SR, Poordad F, Leong S, Teitelbaum UR, et al. (2011). Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis. J Clin Oncol 29 (4s): abstr 261.
153. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Menoret E, Bataille R, et al. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 72: 4562-4573.
154. Szegezdi E, van der Sloot AM, Mahalingam D, O'Leary L, Cool RH, Munoz IG, et al. (2012). Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL. Mol Cell Proteomics 11: M111.013730.
155. Takimoto R, El-Deiry WS, (2000). Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19: 1735-1743.
156. Tang CH, Liu XQ, Yang SF, Zhu B, Gao HJ, (2008). Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo. Zhonghua Zhong Liu Za Zhi 30: 808-812.
157. Tang YM, Yang SF, Zhu B, Cui JS, (2005). Therapeutic effects of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on non-small lung cell cancer: an experimental with rats. Zhonghua Yi Xue Za Zhi 85: 2021-2025.
158. Tolcher AW, (2005). Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin Adv Hematol Oncol 3: 635-642, 662.
159. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, et al. (2007). Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395.
160. Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, et al. (2008). P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene 27: 4161-4171.
161. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, et al. (2010). Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512.
162. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, Ten Hagen TL, (2000). TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82: 973-980.
163. Verbrugge I, Wissink EH, Rooswinkel RW, Jongsma J, Beltraminelli N, Dupuis M, et al. (2009). Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res 15: 2031-2038.
164. Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J, (2010). Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 17: 551-561.
165. Von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, et al. (2010). A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. J Clin Oncol 28 (18s): abstr LBA7501.
166. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, et al. (2007). Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 13: 1070-1077.
167. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, et al. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21: 376-381.
168. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163.
169. Walczak H, Bouchon A, Stahl H, Krammer PH, (2000). Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res 60: 3051-3057.
170. Wang S, El-Deiry WS, (2004). Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 64: 6666-6672.
171. Wang YR, Wen SP, Wang FX, Wen L, Yang BY, Yang JC, et al. (2008). Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 1055-1059.
172. Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G, (2010). Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ 17: 942-951.
173. Wittebol S, Ferrant A, Wickham NW, Fehrenbacher L, Durbin-Johnson B, Bray G, (2010). Phase II study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol 28 (15s): abstr e18511.
174. Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, et al. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143.
175. Xin Y, Tohnya TM, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer PJ, et al. (2008). Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma. J Clin Oncol 26 (20S): abstr 2525.
176. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, et al. (2008). A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 19: 1060-1067.
177. Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, et al. (2007). A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol 25 (18S): abstr 8078.
178. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, et al. (2009). Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. J Clin Oncol 27 (15s): abstr 4129.
179. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, Ansell SM, et al. (2010). A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 103: 1783-1787.
180. Zhang XJ, Wen L, Wang FX, Luo JM, Pan L, Liu XJ, et al. (2006). Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14: 1123-1128.
181. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, et al. (2010). Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. Cancer Lett 297: 155-164.
182. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, et al. (2009). Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther 8: 2969-2980.